Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

RYBREVANT® (amivantamab-vmjw)

Medical Information

RYBREVANT - Dosage and Administration - Use of Peripheral vs Central Intravenous Line

Last Updated: 06/27/2025

Abbreviations: C, cycle; D, day; EGFR, epidermal growth factor receptor; IgG1, immunoglobulin G1; IRR, infusion-related reaction; IV, intravenous; MET, mesenchymal-epithelial transition; MOA, mechanism of action; NSCLC, non-small cell lung cancer; W, week.
^aMoores (2016).¹^bData on File (2023).² ^cPark (2023).³

Literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and DerwentDrug File (and/or other resources, including internal/external databases) was conducted on 18 June 2025.

References

Show

1	Moores SL, Chiu ML, Bushey BS, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016;76(13):3942-3953.
2	Data on File. Amivantamab Intravenous Formulation Company Core Data Sheet. Janssen Research & Development, LLC. EDMS-ERI-206387231; 2025.
3	Park K, Sabari JK, Haura EB, et al. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. Lung Cancer. 2023;178:166-171.

Endchat

Chat live